Stock 002007 HUALAN BIOLOGICAL ENGINEERING INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Hualan Biological Engineering Inc.

Equities

002007

CNE000001JN8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
19.09 CNY +0.05% Intraday chart for Hualan Biological Engineering Inc. +0.10% -13.74%
Apr. 02 Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates MT
Mar. 30 Hualan Biological Engineering Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Hualan Biological Engineering, Inc. specializes in the research, development, manufacturing and marketing of biological and sanguine products and vaccines. The group's products include immunoglobulin for intravenous injections, lyophilized surgical fibrin, lyophilized thrombin for external use, vaccines against cold, etc.

Number of employees: 3,709

Sales per Business

CNY in Million2022Weight2023Weight Delta
Flu Vaccine
45.0 %
1,818 40.2 % 2,403 45.0 % +32.19%
Human Serum Albumin
19.8 %
988 21.9 % 1,057 19.8 % +6.97%
Other Blood Products
19.2 %
916 20.3 % 1,025 19.2 % +11.87%
Intravenous C-ball
15.8 %
775 17.2 % 845 15.8 % +8.96%
Other
0.2 %
20 0.4 % 13 0.2 % -36.17%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
99.7 %
4,499 99.6 % 5,327 99.7 % +18.40%
Foreign
0.3 %
18 0.4 % 15 0.3 % -17.33%

Managers

Managers TitleAgeSince
Bei Fan CEO
 Chief Executive Officer 52 92-03-29
Jun Min Xie DFI
 Director of Finance/CFO 56 10-09-30
Kang An CHM
 Chairman 75 92-02-29
Xiao Wei Ma CTO
 Chief Tech/Sci/R&D Officer 56 07-04-11
Wen Jue An BRD
 Director/Board Member 35 15-05-31
Yan Chao Wang BRD
 Director/Board Member 35 11-06-30
Wen Qi An BRD
 Director/Board Member 45 09-06-30
Bao Xian Zhang BRD
 Director/Board Member 53 08-03-25
Ruo Wen Pan BRD
 Director/Board Member 56 93-01-31
Yuan Cheng Lou IRC
 Investor Relations Contact 40 08-05-31

Members of the board

Members of the board TitleAgeSince
Kang An CHM
 Chairman 75 92-02-29
Bei Fan CEO
 Chief Executive Officer 52 92-03-29
Ruo Wen Pan BRD
 Director/Board Member 56 93-01-31
Xiao Wei Ma CTO
 Chief Tech/Sci/R&D Officer 56 07-04-11
Bao Xian Zhang BRD
 Director/Board Member 53 08-03-25
Lin Lin Cai BRD
 Director/Board Member 38 08-03-31
Wen Qi An BRD
 Director/Board Member 45 09-06-30
Yan Chao Wang BRD
 Director/Board Member 35 11-06-30
Wan Li Liu BRD
 Director/Board Member 43 20-04-14
Wen Jue An BRD
 Director/Board Member 35 15-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,833,195,126 952,293,137 ( 51.95 %) 4,414,200 ( 0.2408 %) 51.95 %

Shareholders

NameEquities%Valuation
Kang An
37.92 %
595,964,484 37.92 % 1 663 M ¥
China Securities Finance Corp. Ltd.
3.450 %
54,229,697 3.450 % 151 M ¥
Da Cheng Fund Management Co., Ltd.
1.387 %
21,799,247 1.387 % 61 M ¥
China Merchants Fund Management Co., Ltd.
1.287 %
20,233,032 1.287 % 56 M ¥
Huatai-PineBridge Fund Management Co., Ltd.
1.039 %
16,331,851 1.039 % 46 M ¥
Yongkang Shengkang Enterprise Management Consulting Ctr LP
0.8590 %
13,502,045 0.8590 % 38 M ¥
Yinhua Fund Management Co., Ltd.
0.8277 %
13,009,477 0.8277 % 36 M ¥
Wen Shi
0.7984 %
12,550,000 0.7984 % 35 M ¥
Abu Dhabi Investment Authority (Investment Management)
0.5848 %
9,192,498 0.5848 % 26 M ¥
Guotai Asset Management Co., Ltd.
0.5838 %
9,176,145 0.5838 % 26 M ¥
NameEquities%Valuation
Kang An
96.98 %
244,895,554 96.98 % 683 M ¥

Company contact information

Hualan Biological Engineering, Inc.

1 Hualan Avenue

453003, Xinxiang

+

http://www.hualanbio.com
address Hualan Biological Engineering Inc.(002007)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Hualan Biological Engineering Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
19.09 CNY
Average target price
25.78 CNY
Spread / Average Target
+35.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HUALAN BIOLOGICAL ENGINEERING INC. Stock Hualan Biological Engineering Inc.
-13.74% 4.82B
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+55.89% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.29% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 002007 Stock
  4. Company Hualan Biological Engineering Inc.